Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
DISEASE OF THE MONTH
You have accessRestricted Access

Acquired Ultrafiltration Dysfunction in Peritoneal Dialysis Patients

Peter J. Margetts, David N. Churchill and ; Feature Editor
JASN November 2002, 13 (11) 2787-2794;
Peter J. Margetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David N. Churchill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Eberhard Ritz

Background

Peritoneal dialysis (PD) is used by over 100,000 end-stage renal disease (ESRD) patients worldwide, accounting for approximately 15% of the dialysis population (1). The relative value of PD is still uncertain and contested due to a lack of randomized clinical trials comparing dialysis modalities. However, clinical experience with PD suggests that it is a useful early therapy in ESRD and is a necessary third modality to complement hemodialysis and transplantation.

Along with peritonitis and inadequate removal of uremic toxins, ultrafiltration (UF) dysfunction is a major clinical limitation of PD. Over time, PD patients develop an increased transport of low-molecular weight solutes across the peritoneal membrane with a concomitant decrease in ultrafiltration (2). The capillary wall of peritoneal blood vessels plays a key role as a barrier to solute transport (3). Therefore, neovascularization of the peritoneal tissues is a main determinant of the functional changes in the peritoneal membrane. This increased vascular surface area leads to an increase in glucose transport from the peritoneal cavity with rapid loss of the osmotic gradient. The role of increased fluid absorption from the peritoneum by tissue and lymphatics (4), along with dysfunction of aquaporins in the peritoneal vessels (5), is less well defined.

A recent randomized controlled trial of adequacy of dialysis in Mexico (ADEMEX), reports no difference in all-cause mortality between PD patients dialyzed to a weekly total Kt/V of 1.7 compared with the recommended target of 2.0 (6). An increase in deaths due to uremia and congestive heart failure in the group with the lower Kt/V in the ADEMEX study suggests that adequacy should still be monitored clinically (7). Moreover, these results indicate that more attention needs to be paid to overall management of PD patients, particularly with respect to volume control and preservation of peritoneal membrane ultrafiltration capacity.

Definition and Clinical Approach

Earlier studies defined UF dysfunction clinically as an increasing requirement for high osmolarity dialysate (3 or more 3.86% glucose solution exchanges daily) to maintain an edema-free target weight (8). More recent studies have utilized objective criteria with a 4-h peritoneal equilibrium test (PET) using a high-concentration glucose dialysate solution where UF failure is defined as a net UF <400 ml/4 h (9,10). The standard PET using a 2.5% glucose solution and UF failure defined as <100 ml/4 h net ultrafiltration probably overestimates the occurrence of ultrafiltration dysfunction (10).

The recommended clinical approach to UF dysfunction has been outlined by a recent ISPD committee report (11). The first step is the recognition of UF dysfunction and the clinical manifestation, extravascular volume expansion. In the absence of any widely used ancillary measure of extravascular fluid volume, this is accomplished through careful clinical evaluation. The next step is to eliminate easily remediable problems. These include patient factors (e.g., dietary compliance), physician factors (inappropriate PD prescription), and mechanical factors (catheter malposition, extraperitoneal leakage). After evaluation of these easily remediable causes of volume expansion, peritoneal membrane dysfunction is, by exclusion, the diagnosis.

Epidemiology

In various studies, the prevalence of UF dysfunction leading to technique failure has been reported between 1.7% (12) and 13.7% (13). These data are confounded by the difficulty in accurately diagnosing the cause of technique failure. Using a clinical definition of UF dysfunction, prevalence rates have been reported between 15.3% (14) and 30.9% (8). Ho-dac-Pannekeet et al. (10) used the recommended 4-h high osmolarity PET and found the prevalence of UF dysfunction to be 23% in a group of 68 stable PD patients.

Changes in the peritoneal membrane function over time have been documented in several studies and recently reviewed (15). The majority of longitudinal studies of peritoneal membrane function find an increase in low-molecular weight solute transport with time on dialysis and a coincident decrease in ultrafiltration (2,16). The onset of UF dysfunction appears between 2 (17) and 4 (2) yr after the initiation of PD. The inverse correlation between UF and solute transport has been clearly demonstrated in these studies. Lo et al. (18) demonstrated a centripetal effect of membrane function over time. Among 55 PD patients followed for a mean of 22 mo, there was an increase in solute transport in patients with initial low transport peritoneal membranes and a decrease in solute transport in high transporters over time. One possible explanation is a selective censoring by technique failure or death of high-transport patients while there is increased transport in the low-transport groups over time (15). This may also explain to some extent the apparent stability of peritoneal membrane function over the first 2 to 4 yr of PD.

Pathophysiology

Ultrafiltration across the peritoneal membrane is the net effect of the osmotic force pulling fluid into the peritoneal cavity and hydrostatic forces pushing fluid into the interstitium and lymphatic reabsorption. The membrane across which the osmotic force acts has been described as a theoretical three-pore model (19). Ultrasmall pores correspond to aquaporin channels located on peritoneal venules and capillaries (5) and usually supply 40% of the net ultrafiltration (20). Small-sized pores are the major conduit for solute and fluid ultrafiltration. Large pores are few in number and allow for macromolecular transport. The major determinant of the prevalence of the small pores is the vascular surface area, which explains why increased vascularization of the peritoneal tissues will lead to rapid glucose transport, loss of osmotic gradient, and loss of ultrafiltration (3).

The peritoneal membrane is composed of an outer mesothelial cell layer and a basement membrane overlying a thin interstitial layer of connective tissue and blood vessels. In a recent large peritoneal biopsy study, Williams et al. (21) analyzed samples from 212 subjects including normal individuals as well as uremic and peritoneal dialysis patients. There was an increase in the thickness of the submesothelial tissue with uremia, which further increased with peritoneal dialysis. The vascular sclerosis, recognized in other biopsy studies (22), was correlated with time on peritoneal dialysis. The number of blood vessels in the submesothelial tissue did not correlate with time on dialysis. However, there was a significant increase in vascularization in patients whose biopsy was performed at catheter removal due to membrane failure (21).

Increased Vascular Surface Area

Increased vascularization of the peritoneal tissue is the primary mechanism of ultrafiltration failure. Between 50 and 75% of patients with UF dysfunction will have increased vascular area measured by increased small solute transport on a standard PET (8,10). In animal models of peritoneal dialysate exposure, an increase in submesothelial vascularization correlates directly with glucose absorption and inversely with net UF (23). Furthermore, reduction of peritoneal vasculature by anti-angiogenic therapy led to an improvement in net UF (23). Human biopsy studies confirm the association between submesothelial vascularization and UF dysfunction (21,22).

Aquaporin Dysfunction

Aquaporin dysfunction is a possible cause of UF failure in some patients. Monquil et al. (24) and colleagues studied six PD patients with severe UF dysfunction, normal small molecular transport rate, and low interstitial/lymphatic absorption rate. They suggested that aquaporin dysfunction was the remaining possible mechanism for UF dysfunction. Hyperosmolar PD solutions (3.86% glucose) did not improve ultrafiltration, and five of six patients required transfer to hemodialysis. However, the ability to accurately measure aquaporin function using a standard peritoneal function test with hyperosmolar solution (3.86% glucose) has been questioned (20). Also, normal aquaporin expression by immunohistochemistry of peritoneal tissue was found in a patient with presumed aquaporin dysfunction by clinical evaluation (25). Alteration of the function of the aquaporin channel could explain this finding, but more work needs to be carried out in this area.

Increased Interstitial/Lymphatic Absorption

Fluid reabsorption from the peritoneal cavity into tissues and lymphatics is a recognized mechanism of UF failure (4) and accounts for approximately 25% of the cases of UF dysfunction (8,26). The interstitium of the peritoneal tissue consists mainly of collagen fibers and glycosaminoglycans. Alterations in the constitution of the interstitium may lead to changes in hydrodynamic properties and macromolecular transport. Hydration will tend to expand the extracellular matrix and increase fluid conductance (27). Risk factors for increased tissue and lymphatic reabsorption have not been identified, but recently, Fussholler et al. (28) identified an association between increased fluid reabsorption and time on dialysis.

Etiology

The observation that UF dysfunction increases with time on PD (16) has led to the conclusion that elements of the PD fluid are bioincompatible and damage the peritoneal membrane (Figure 1). Several studies have documented progressive UF dysfunction in patients even in the absence of peritonitis (2). Animal models have confirmed the detrimental effect of peritoneal dialysate on the peritoneum (29). Putative bioincompatible components of standard PD fluid include glucose, glucose degradation products (GDP), lactate buffer, or acidic pH. The bioincompatible nature of low pH and buffer is not clear, but it appears to be less important than glucose or GDP (30).

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Components of peritoneal membrane dysfunction, components of ultrafiltration dysfunction, and outcomes of ultrafiltration failure.

Davies et al. (31) have shown that increased exposure to hyperosmolar glucose dialysate predated by 2 yr the onset of UF dysfunction (31). In this case control study, patients with increasingly permeable peritoneal membranes also had an early loss of residual renal function, which probably required increased use of glucose to replace renal ultrafiltration. Selgas et al. (32) identified a similar effect with increased glucose exposure and diabetes, both associated with early UF dysfunction.

GDP are reactive carbonyl compounds produced in peritoneal dialysate during the process of heat sterilization. GDP, such as methylglyoxal, glyoxal, and 3-deoxyglucasone, have been shown to be more potent inducers of advanced glycation end-products (AGE) than glucose alone (33). GDP have been shown to alter mesothelial cell function and proliferation (34) and to induce vascular endothelial growth factor (VEGF) production in vitro (35). In animal models, conventional dialysate fluid induced vasodilation and capillary recruitment in the peritoneal tissues, whereas GDP-reduced dialysate did not induce these changes (30).

Peritonitis is a major cause of peritoneal membrane dysfunction. There is an acute effect of peritonitis that lasts for a month after the infectious event and clinically appears as decreased UF with increased solute transport. Ates et al. (36) have suggested a subtle longer-term UF dysfunction after a single episode of peritonitis. Others report that one episode of peritonitis has little long-term effect (2). However, multiple or severe infective episodes may have a greater long-term impact on the peritoneal membrane function (2).

The mechanism of long-term changes after peritonitis episodes may be due to an upregulation of inflammatory cytokines or profibrotic cytokines, such as TGF-β and fibroblast growth factor (FGF) (37). In an animal model of acute peritonitis, Combet et al. (38) demonstrated increased expression of endothelial nitric oxide synthase (NOS) in the peritoneal tissues. This was associated with increased vascularization, increased protein loss, and UF failure. Using adenovirus mediated gene transfer of inflammatory cytokines IL-1β and TNF-α, longer term effects on vascularization and fibrosis can be induced in the peritoneum after transient cytokine overexpression and IL-1β appears to be more potent in inducing these changes (39). Therefore, there are pathways from acute inflammation to longer-term fibrosis and angiogenesis in the peritoneum that may explain the association between peritonitis and UF dysfunction seen in several observational studies.

The uremic environment may be associated with altered peritoneal membrane structure and function. In rats made uremic with subtotal nephrectomy, significant changes in the peritoneal tissues occurred, including increased AGE deposition, increased vascularization with increased expression of NOS, VEGF, and FGF-2 (40). The effect of uremia on the peritoneal tissues has been confirmed in peritoneal biopsy studies that included uremic, nondialyzed patients, which demonstrated increased submesothelial thickening in these patients (21).

In PD patients, the association between peritoneal membrane transport properties and markers of systemic inflammation has been controversial. Wang et al. (41) did not find any association between membrane transport and numerous markers of inflammation assessed. In a second study, high C-reactive protein and declining residual renal function were both associated with increasing peritoneal membrane transport status from initiation to 1 yr on dialysis (42). In a retrospective study, we found that patients with a high transport peritoneal membrane had low serum albumin before the initiation of PD and suggested this was the result of systemic factors such as inflammation or overhydration (43).

Outcomes

Several factors, including low serum albumin, age, comorbid disease, and residual renal function, are known to be predictive of survival in PD patients. High transport status at the initiation of dialysis has also been shown to be associated with decreased UF function and poor outcome (44). Acquired UF dysfunction is associated with decreased survival in several studies. Wang et al. (45) measured the peritoneal membrane function in a cross-section of 46 established PD patients and found increased solute transport to be inversely associated with fluid removal and survival. In a study of 125 incident PD patients, Ates et al. (46) demonstrated the impact of total fluid removal and sodium removal (including peritoneal and renal) on survival. From a large longitudinal database, Davies et al. (47) compared survivors and nonsurvivors and demonstrated that nonsurvivors had a progressive increase in small solute transport with time on dialysis.

UF dysfunction is also associated with other poor prognostic indicators such as clinical volume expansion (48) and diastolic hypertension (49). Volume expansion in PD patients is associated with hypoalbuminemia (50), and adjusting dialysis prescription to increase UF can reduce volume expansion and increase serum albumin (51).

In summary, there is evidence that UF dysfunction is associated with decreased survival in PD patients. UF dysfunction is associated with volume expansion, and this may be associated, through hypertension, left ventricular hypertrophy, preexisting co-morbid disease, systemic inflammation, and hypoalbuminemia, with increased mortality and morbidity, primarily through cardiovascular outcomes (Figure 1).

Treatment

The treatment of UF dysfunction in PD patients involves three steps. First, the problem of UF dysfunction must be recognized through regular clinical volume assessment and routine measurement of peritoneal membrane function, including net UF (11). Prevention, with protection of the peritoneal membrane from injury due to peritonitis and bioincompatible dialysis solutions, is an important second step. Finally, treatment strategies for established UF dysfunction are limited at present, but they should expand with further research in this area.

Icodextrin

Icodextrin is a promising dialysate solution for improving UF function. This glucose polymer solution has been demonstrated to be beneficial in several clinical studies (Table 1). Icodextrin is a colloid and appears to promote UF through small pores in the peritoneal membrane and is therefore effective in PD patients with increased peritoneal vascular area or in the setting of acute peritonitis (52). In large randomized studies in which icodextrin was used in the nighttime dwell in CAPD patients (53) or the daytime dwell in APD patients (54), a similar UF rate was observed to that obtained with a hyperosmolar glucose solution (3.86% glucose). In a smaller observational study, the use of icodextrin in APD patients led to decreased use of hypotensive medication, fall in BP, and decreased extravascular fluid based on bioelectrical impedance analyses (55).

View this table:
  • View inline
  • View popup

Table 1. Treatment trials using icodextrin and biocompatible solutions for ultrafiltration dysfunctiona

Two studies have assessed the value of icodextrin in patients with UF failure (Table 1). The first prospective study took 17 patients with impending technique failure due to UF dysfunction and prescribed icodextrin (56). Net daily UF increased by 570 ml, BP improved, and technique survival was prolonged by 1 yr. Patients who benefited the most from icodextrin were those who initially had very low UF.

Biocompatible Solutions

Biocompatible solutions are produced in two chambered bags so that glucose is separated from the electrolytes at a very low pH. This prevents the formation of GDP during heat sterilization (33) and allows for adjustment of final pH and buffer.

Conventional PD solutions have detrimental effects on cellular proliferation, function, and inflammation, which are reversed by more physiologic solutions (34,57). Animal studies using more physiologic solutions have demonstrated reduced AGE deposition and preserved UF (58).

Several clinical trials of physiologic solutions have been performed, and safety and tolerance have been demonstrated (Table 1) (59). In a 6-mo trial of 106 PD patients randomized to conventional or physiologic solution, Tranaeus (60) found an increase in UF (150 ml/d) with stable peritoneal membrane characteristics. In a voluntary 6-mo extension of this study, significantly lower peritonitis rates were reported in the physiologic solution group. A common finding among clinical trials of physiologic solutions is an increase in effluent CA125, suggesting improved mesothelial cell viability and a decrease in effluent hyaluronan concentration, which is interpreted as a decrease in peritoneal inflammation (61,62)

Other Alternate PD Solutions

Several other dialysate fluids have been tried in an attempt to increase UF. Amino acid solutions represent both an alternate osmotic agent and a source of nutrition. However, as an osmotic agent, amino acids appear to offer similar UF potential as conventional 1.5% glucose solutions (63). Glycerol has the advantage of avoidance of glucose; however, it is rapidly absorbed from the peritoneum. In hyperosmotic solutions, glycerol can provide equivalent UF to glucose (64). Low-sodium solutions have been used in an attempt to increase salt, and therefore water, removal. The results have been inconsistent (65).

Alteration of the Interstitial Compartment

Hyaluronan is a glycosaminoglycan that is present in the interstitium of the peritoneum. In animal models, hyaluronan has been shown to increase net ultrafiltration and decrease markers of inflammation (66,67). These animal studies have also shown a decrease in protein transport into the peritoneal fluid. Aside from demonstrated antiinflammatory properties, hyaluronan is felt to effect the interstitium and fluid absorption from the peritoneum (68).

Small observational studies in humans have been carried out to study the surface active phospholipid phosphatidylcholine and have demonstrated an increase net UF when delivered orally (69) or intraperitoneal (70).

Vasoactive Agents

Several agents with vasoactive properties have been studied. Nitroprusside is a nitric oxide donor and therefore increases the peritoneal vascular surface area and large molecule permeability. These effects would presumably have a negative impact on UF. However, when combined with icodextrin, nitroprusside increased net UF along with small and large molecule clearance in a small observational study in stable PD patients (71). On the other hand, inhibition of NOS should reduce peritoneal vascular surface area and permeability and therefore improve UF. This has been demonstrated in animal studies (72). Finally, angiotensin-converting enzyme inhibition is known to have effects on vasculature and should potentially be beneficial in preserving UF. This has been suggested in animal models (73), but not confirmed in small human studies (74).

Alternative Dialysis Strategies

Alteration of dialysis strategy is another potential technique to treat UF failure. Peritoneal rest has been advocated as an effective strategy and has been demonstrated in a clinical trial of 16 patients who were converted to HD for 4 mo (75). Net daily UF increased from 490 to 880 ml on re-initiation of PD. Increasing volume removal using furosemide or hemofiltration appeared to restore the peritoneal membrane UF capacity in a small study (76).

Automated PD (APD) has been suggested to be a useful therapy in patients with high-transport peritoneal membranes (77). The decreased dwell time with APD will maximize the UF using standard glucose solutions. However, observational studies suggest that APD patients have less sodium and fluid removal with resultant higher BP (78) and increased risk for left ventricular hypertrophy (79).

In summary, icodextrin has the potential to increase UF in patients with increased peritoneal vascular surface area or in the setting of peritonitis and may extend technique survival in patients with impending UF failure. Physiologic solutions hold great promise in the protection of peritoneal function and inflammatory response, but further clinical evidence is required. Pharmacologic agents have not been studied in any reasonably sized clinical trials; however, alteration of the interstitial compartment with modification of fluid reabsorption from the peritoneum may have significant benefits.

Conclusions

The ADEMEX study (6) and reanalysis of the CANUSA data (80) indicate that aspects of PD patient care other than solute removal need to be addressed. UF dysfunction is a major impediment to long-term PD therapy. Volume expansion, which progresses with changes in the peritoneal membrane transport properties and with loss of residual renal function, has a significant impact on the prevalence of cardiac disease in the PD population. UF dysfunction impacts both mortality and technique survival in PD patients.

Ongoing research has led to a further understanding of the mechanisms of UF failure, including increased vascular surface area and rapid glucose absorption, aquaporin dysfunction, and fluid absorption through interstitium and lymphatics. The etiologic agents involved (severe peritonitis, glucose, and bioincompatible dialysate) have been better defined. Future treatment strategies will include better detection of UF dysfunction and volume expansion, prevention of peritoneal membrane damage through new solutions, protection of RRF, and eventually, treatment of established UF failure using altered dialysis prescriptions and solutions, and perhaps pharmacologic intervention. Along with in vitro and animal model work to further define elements of UF failure, well-designed randomized trials are required to answer key clinical questions and improve outcomes for PD patients.

Acknowledgments

We would like to thank the many excellent researchers in peritoneal dialysis around the world whose ideas and insights have been adopted and form the basis for this review. P. Margetts is supported by the Canadian Institutes of Health Research.

  • © 2002 American Society of Nephrology

References

  1. ↵
    Gokal R: Taking peritoneal dialysis beyond the year 2000. Perit Dial Int 19 [Suppl 3]: S35–S42, 1999
  2. ↵
    Davies SJ, Bryan J, Phillips L, Russell GI: Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 11: 498–506, 1996
    OpenUrlCrossRefPubMed
  3. ↵
    Krediet RT, Lindholm B, Rippe B: Pathophysiology of peritoneal membrane failure. Perit Dial Int 20 [Suppl 4]: S22–S42, 2000
    OpenUrlFREE Full Text
  4. ↵
    Mactier RA, Khanna R, Twardowski ZJ, Nolph KD: Ultrafiltration failure in continuous ambulatory peritoneal dialysis due to excessive peritoneal cavity lymphatic absorption. Am J Kidney Dis 10: 461–466, 1987
    OpenUrlPubMed
  5. ↵
    Devuyst O, Nielsen S, Cosyns JP, Smith BL, Agre P, Squifflet JP, Pouthier D, Goffin E: Aquaporin-1 and endothelial nitric oxide synthase expression in capillary endothelia of human peritoneum. Am J Physiol 275: H234–H242, 1998
  6. ↵
    Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13: 1307–1320, 2002
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Churchill DN: The ADEMEX study: make haste slowly. J Am Soc Nephrol 13: 1415–1418, 2002
    OpenUrlFREE Full Text
  8. ↵
    Heimburger O, Waniewski J, Werynski A, Tranaeus A, Lindholm B: Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 38: 495–506, 1990
    OpenUrlCrossRefPubMed
  9. ↵
    Smit W, Langedijk MJ, Schouten N, van den BN, Struijk DG, Krediet RT: A comparison between 1.36% and 3.86% glucose dialysis solution for the assessment of peritoneal membrane function. Perit Dial Int 20: 734–741, 2000
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Ho-dac-Pannekeet MM, Atasever B, Struijk DG, Krediet RT: Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis. Perit Dial Int 17: 144–150, 1997
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Mujais S, Nolph K, Gokal R, Blake P, Burkart J, Coles G, Kawaguchi Y, Kawanishi H, Korbet S, Krediet R, Lindholm B, Oreopoulos D, Rippe B, Selgas R: Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 20 [Suppl 4]: S5–21, 2000
    OpenUrlAbstract
  12. ↵
    Maiorca R, Cancarini GC, Zubani R, Camerini C, Manili L, Brunori G, Movilli E: CAPD viability: A long-term comparison with hemodialysis. Perit Dial Int 16: 276–287, 1996
    OpenUrlAbstract
  13. ↵
    Kawaguchi Y: National comparisons: Optimal peritoneal dialysis outcomes among Japanese patients. Perit Dial Int 19 Suppl 3: S9–16, 1999
  14. ↵
    Slingeneyer A, Canaud B, Mion C: Permanent loss of ultrafiltration capacity of the peritoneum in long-term peritoneal dialysis: An epidemiological study. Nephron 33: 133–138, 1983
    OpenUrlPubMed
  15. ↵
    De Vriese AS, Mortier S, Lameire NH: What happens to the peritoneal membrane in long-term peritoneal dialysis? Perit Dial Int 21 [Suppl 3]: S9–18, 2001
    OpenUrlFREE Full Text
  16. ↵
    Heimburger O, Wang T, Lindholm B: Alterations in water and solute transport with time on peritoneal dialysis. Perit Dial Int 19 [Suppl 2]: S83–S90, 1999
  17. ↵
    Struijk DG, Krediet RT, Koomen GC, Boeschoten EW, Hoek FJ, Arisz L: A prospective study of peritoneal transport in CAPD patients. Kidney Int 45: 1739–1744, 1994
    OpenUrlCrossRefPubMed
  18. ↵
    Lo WK, Brendolan A, Prowant BF, Moore HL, Khanna R, Twardowski ZJ, Nolph KD: Changes in the peritoneal equilibration test in selected chronic peritoneal dialysis patients. J Am Soc Nephrol 4: 1466–1474, 1994
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Rippe B, Stelin G, Haraldsson B: Computer simulations of peritoneal fluid transport in CAPD. Kidney Int 40: 315–325, 1991
    OpenUrlCrossRefPubMed
  20. ↵
    Rippe B, de Arteaga J, Venturoli D: Aquaporins are unlikely to be affected in marked ultrafiltration failure: Results from a computer simulation. Perit Dial Int 21 [Suppl 3]: S30–S34, 2001
    OpenUrlFREE Full Text
  21. ↵
    Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT, Peritoneal Biopsy Study Group: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 13: 470–479, 2002
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Mateijsen MA, van der Wal AC, Hendriks PM, Zweers MM, Mulder J, Struijk DG, Krediet RT: Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 19: 517–525, 1999
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Margetts PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, Gauldie J: Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 13: 721–728, 2002
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Monquil MC, Imholz AL, Struijk DG, Krediet RT: Does impaired transcellular water transport contribute to net ultrafiltration failure during CAPD? Perit Dial Int 15: 42–48, 1995
  25. ↵
    Goffin E, Combet S, Jamar F, Cosyns JP, Devuyst O: Expression of aquaporin-1 in a long-term peritoneal dialysis patient with impaired transcellular water transport. Am J Kid Disease 33: 383–388, 1999
    OpenUrlCrossRefPubMed
  26. ↵
    Pollock CA, Ibels LS, Hallett MD, Cocksedge B, Caterson RJ, Mahony JF, Farrell PC: Loss of ultrafiltration in continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 9: 107–110, 1989
  27. ↵
    Flessner MF: Changes in the peritoneal interstitium and their effect on peritoneal transport. Perit Dial Int 19 [Suppl 2]: S77–S82, 1999
  28. ↵
    Fussholler A, zur NS, Grabensee B, Plum J: Peritoneal fluid and solute transport: Influence of treatment time, peritoneal dialysis modality, and peritonitis incidence. J Am Soc Nephrol 13: 1055–1060, 2002
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Zweers MM, Splint LJ, Krediet RT, Struijk DG: Ultrastructure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat. Nephrol Dial Transplant 16: 651–654, 2001
    OpenUrlCrossRefPubMed
  30. ↵
    Mortier S, De Vriese AS, Van d, V, Schaub TP, Passlick-Deetjen J, Lameire NH: Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: Role of acidity, buffer choice, glucose concentration, and glucose degradation products. J Am Soc Nephrol 13: 480–489, 2002
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Davies SJ, Phillips L, Naish PF, Russell GI: Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 12: 1046–1051, 2001
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Selgas R, Bajo MA, Castro MJ, del Peso G, Aguilera A, Fernandez-Perpen A, Cirugeda A, Sanchez-Tomero JA: Risk factors responsible for ultrafiltration failure in early stages of peritoneal dialysis. Perit Dial Int 20: 631–636, 2000
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Tauer A, Knerr T, Niwa T, Schaub TP, Lage C, Passlick-Deetjen J, Pischetsrieder M: In vitro formation of N(epsilon)-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 280: 1408–1414, 2001
    OpenUrlCrossRefPubMed
  34. ↵
    Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jorres A: Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 12: 2434–2441, 2001
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, van Ypersele dS, Kurokawa K: Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: Role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 463: 260–264, 1999
    OpenUrlCrossRefPubMed
  36. ↵
    Ates K, Koc R, Nergizoglu G, Erturk S, Keven K, Sen A, Karatan O: The longitudinal effect of a single peritonitis episode on peritoneal membrane transport in CAPD patients. Perit Dial Int 20: 220–226, 2000
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Lai KN, Lai KB, Lam CW, Chan TM, Li FK, Leung JC: Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kid Disease 35: 644–652, 2000
    OpenUrlPubMed
  38. ↵
    Combet S, Van Landschoot M, Moulin P, Piech A, Verbavatz JM, Goffin E, Balligand JL, Lameire N, Devuyst O: Regulation of aquaporin-1 and nitric oxide synthase isoforms in a rat model of acute peritonitis. J Am Soc Nephrol 10: 2185–2196, 1999
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Margetts PJ, Kolb M, Yu L, Hoff CM, Holmes CJ, Anthony DC, Gauldie J: Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol 160: 2285–2294, 2002
    OpenUrlCrossRefPubMed
  40. ↵
    Combet S, Ferrier ML, Van Landschoot M, Stoenoiu M, Moulin P, Miyata T, Lameire N, Devuyst O: Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 12: 2146–2157, 2001
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Wang T, Heimburger O, Cheng HH, Bergstrom J, Lindholm B: Does a high peritoneal transport rate reflect a state of chronic inflammation? Am J Kid Disease 19: 17–22, 1999
    OpenUrl
  42. ↵
    Chung SH, Heimburger O, Stenvinkel P, Bergstrom J, Lindholm B: Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant 16: 2240–2245, 2001
    OpenUrlCrossRefPubMed
  43. ↵
    Margetts PJ, McMullin JP, Rabbat CG, Churchill DN: Peritoneal membrane transport and hypoalbuminemia: Cause or effect? Perit Dial Int 20: 14–18, 2000
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Page D: Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 9: 1285–1292, 1998
    OpenUrlAbstract
  45. ↵
    Wang T, Heimburger O, Waniewski J, Bergstrom J, Lindholm B: Increased peritoneal permeability is associated with decreased fluid and small-solute removal and higher mortality in CAPD patients. Nephrol Dial Transplant 13: 1242–1249, 1998
    OpenUrlCrossRefPubMed
  46. ↵
    Ates K, Nergizoglu G, Keven K, Sen A, Kutlay S, Erturk S, Duman N, Karatan O, Ertug AE: Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 60: 767–776, 2001
    OpenUrlCrossRefPubMed
  47. ↵
    Davies SJ, Phillips L, Russell GI: Peritoneal solute transport predicts survival on CAPD independently of residual renal function. Nephrol Dial Transplant 13: 962–968, 1998
    OpenUrlCrossRefPubMed
  48. ↵
    Tzamaloukas AH, Saddler MC, Murata GH, Malhotra D, Sena P, Simon D, Hawkins KL, Morgan K, Nevarez M, Wood B: Symptomatic fluid retention in patients on continuous peritoneal dialysis. J Am Soc Nephrol 6: 198–206, 1995
    OpenUrlAbstract
  49. ↵
    Bos WJ, Struijk DG, van Olden RW, Arisz L, Krediet RT: Elevated 24-hour blood pressure in peritoneal dialysis patients with ultrafiltration failure. Adv Peritoneal Dial 14: 108–110, 1998
    OpenUrl
  50. ↵
    Jones CH, Smye SW, Newstead CG, Will EJ, Davison AM: Extracellular fluid volume determined by bioelectric impedance and serum albumin in CAPD patients. Nephrol Dial Transplant 13: 393–397, 1998
  51. ↵
    Jones CH, Wells L, Stoves J, Farquhar F, Woodrow G: Can a reduction in extracellular fluid volume result in increased serum albumin in peritoneal dialysis patients? Am J Kidney Dis 39: 872–875, 2002
    OpenUrlCrossRefPubMed
  52. ↵
    Gokal R, Mistry CD, Peers EM: Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Dialysis. Perit Dial Int 15: 226–230, 1995
    OpenUrlAbstract/FREE Full Text
  53. ↵
    Mistry CD, Gokal R, Peers E: A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 46: 496–503, 1994
    OpenUrlCrossRefPubMed
  54. ↵
    Posthuma N, ter Wee PM, Verbrugh HA, Oe PL, Peers E, Sayers J, Donker AJ: Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrol Dial Transplant 12: 550–553, 1997
    OpenUrlCrossRefPubMed
  55. ↵
    Woodrow G, Oldroyd B, Stables G, Gibson J, Turney JH, Brownjohn AM: Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis. Nephrol Dial Transplant 15: 862–866, 2000
    OpenUrlCrossRefPubMed
  56. ↵
    Johnson DW, Arndt M, O’Shea A, Watt R, Hamilton J, Vincent K: Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload. BMC Nephrol 2: 2, 2001
    OpenUrlCrossRefPubMed
  57. ↵
    Jones S, Holmes CJ, Mackenzie RK, Stead R, Coles GA, Williams JD, Faict D, Topley N: Continuous dialysis with bicarbonate/lactate-buffered peritoneal dialysis fluids results in a long-term improvement in ex vivo peritoneal macrophage function. J Am Soc Nephrol 13 [Suppl 1]: S97–S103, 2002
    OpenUrlAbstract/FREE Full Text
  58. ↵
    Park MS, Kim JK, Holmes C, Weiss MF: Effects of bicarbonate/lactate solution on peritoneal advanced glycosylation end-product accumulation. Perit Dial Int 20 [Suppl 5]: S33–S38, 2000
    OpenUrlAbstract/FREE Full Text
  59. ↵
    Coles GA, Gokal R, Ogg C, Jani F, O’Donoghue DT, Cancarini GC, Maiorca R, Tranaeus A, Faict D, De Vos C, Cancarinu GC: A randomized controlled trial of a bicarbonate- and a bicarbonate/lactate-containing dialysis solution in CAPD. Perit Dial Int 17: 48–51, 1997
    OpenUrlAbstract/FREE Full Text
  60. ↵
    Tranaeus A: A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution-clinical benefits. The Bicarbonate/Lactate Study Group. Perit Dial Int 20: 516–523, 2000
    OpenUrlAbstract/FREE Full Text
  61. ↵
    Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G, Weiss L, Nielsen FD, Bro S, Friedberg M, Wieslander A: Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 59: 348–357, 2001
    OpenUrlCrossRefPubMed
  62. ↵
    Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, Williams JD, Coles GA, Topley N, Bicarbonate/Lactate Study Group: Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 59: 1529–1538, 2001
    OpenUrlCrossRefPubMed
  63. ↵
    Plum J, Fussholler A, Schoenicke G, Busch T, Erren C, Fieseler C, Kirchgessner J, Passlick-Deetjen J, Grabensee B: In vivo and in vitro effects of amino-acid-based and bicarbonate-buffered peritoneal dialysis solutions with regard to peritoneal transport and cytokines/prostanoids dialysate concentrations. Nephrol Dial Transplant 12: 1652–1660, 1997
    OpenUrlCrossRefPubMed
  64. ↵
    Smit W, de Waart DR, Struijk DG, Krediet RT: Peritoneal transport characteristics with glycerol-based dialysate in peritoneal dialysis. Peritoneal Dial Int 20: 557–565, 2000
    OpenUrlAbstract/FREE Full Text
  65. ↵
    Imholz AL, Koomen GC, Struijk DG, Arisz L, Krediet RT: Fluid and solute transport in CAPD patients using ultralow sodium dialysate. Kidney Int 46: 333–340, 1994
    OpenUrlCrossRefPubMed
  66. ↵
    Breborowicz A, Polubinska A, Moberly J, Ogle K, Martis L, Oreopoulos D: Hyaluronan modifies inflammatory response and peritoneal permeability during peritonitis in rats. Am J Kidney Dis[computer file] 37: 594–600, 2001
    OpenUrlPubMed
  67. ↵
    Guo QY, Peng WX, Cheng HH, Ye RG, Lindholm B, Wang T: Hyaluronan preserves peritoneal membrane transport properties. Perit Dial Int 21: 136–142, 2001
    OpenUrlAbstract/FREE Full Text
  68. ↵
    Rosengren BI, Carlsson O, Rippe B: Hyaluronan and peritoneal ultrafiltration: A test of the ‘filter-cake‘ hypothesis. Am J Kidney Dis 37: 1277–1285, 2001
    OpenUrlPubMed
  69. ↵
    Chan H, Abraham G, Oreopoulos DG: Oral lecithin improves ultrafiltration in patients on peritoneal dialysis [see comments]. Perit Dial Int 9: 203–205, 1989
  70. ↵
    Krack G, Viglino G, Cavalli PL, Gandolfo C, Magliano G, Cantaluppi A, Peluso F: Intraperitoneal administration of phosphatidylcholine improves ultrafiltration in continuous ambulatory peritoneal dialysis patients [see comments]. Perit Dial Int 12: 359–364, 1992
  71. ↵
    Douma CE, Hiralall JK, de Waart DR, Struijk DG, Krediet RT: Icodextrin with nitroprusside increases ultrafiltration and peritoneal transport during long CAPD dwells. Kidney Int 53: 1014–1021, 1998
    OpenUrlCrossRefPubMed
  72. ↵
    Ferrier ML, Combet S, Van Landschoot M, Stoenoiu MS, Cnops Y, Lameire N, Devuyst O: Inhibition of nitric oxide synthase reverses changes in peritoneal permeability in a rat model of acute peritonitis. Kidney Int 60: 2343–2350, 2001
    OpenUrlCrossRefPubMed
  73. ↵
    Duman S, Gunal AI, Sen S, Asci G, Ozkahya M, Terzioglu E, Akcicek F, Atabay G: Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int 21: 219–224, 2001
    OpenUrlAbstract/FREE Full Text
  74. ↵
    Ripley EB, Gehr TW, Kish CW, Sica DA: Hormonal, blood pressure, and peritoneal transport response to short-term ACE inhibition. Perit Dial Int 14: 378–383, 1994
  75. ↵
    de Alvaro F, Castro MJ, Dapena F, Bajo MA, Fernandez-Reyes MJ, Romero JR, Jimenez C, Miranda B, Selgas R: Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure. Adv Perit Dial 9: 56–61, 1993
    OpenUrlPubMed
  76. ↵
    Bazzato G, Coli U, Landini S, Lucatello S, Fracasso A, Righetto F, Scanferla F, Morachiello P: Restoration of ultrafiltration capacity of peritoneal membrane in patients on CAPD. Int J Artificial Organs 7: 93–96, 1984
  77. ↵
    Churchill DN: Patient selection for automated peritoneal dialysis on the basis of peritoneal transport characteristics. Contrib Nephrol 129: 69–74, 1999
    OpenUrlPubMed
  78. ↵
    Ortega O, Gallar P, Carreno A, Gutierrez M, Rodriguez I, Oliet A, Vigil A, Gimenez E: Peritoneal sodium mass removal in continuous ambulatory peritoneal dialysis and automated peritoneal dialysis: influence on blood pressure control. Am J Nephrol 21: 189–193, 2001
    OpenUrlCrossRefPubMed
  79. ↵
    Wang MC, Tseng CC, Tsai WC, Huang JJ: Blood pressure and left ventricular hypertrophy in patients on different peritoneal dialysis regimens. Perit Dial Int 21: 36–42, 2001
    OpenUrlAbstract/FREE Full Text
  80. ↵
    Bargman JM, Thorpe KE, Churchill DN: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol 12: 2158–2162, 2001
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 13 (11)
Journal of the American Society of Nephrology
Vol. 13, Issue 11
1 Nov 2002
  • Table of Contents
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Acquired Ultrafiltration Dysfunction in Peritoneal Dialysis Patients
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Acquired Ultrafiltration Dysfunction in Peritoneal Dialysis Patients
Peter J. Margetts, David N. Churchill
JASN Nov 2002, 13 (11) 2787-2794;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Acquired Ultrafiltration Dysfunction in Peritoneal Dialysis Patients
Peter J. Margetts, David N. Churchill
JASN Nov 2002, 13 (11) 2787-2794;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Background
    • Epidemiology
    • Pathophysiology
    • Etiology
    • Outcomes
    • Treatment
    • Conclusions
    • Acknowledgments
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Exercise in the End-Stage Renal Disease Population
  • Nephronophthisis-Associated Ciliopathies
  • Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease
Show more Disease of the Month

Cited By...

  • Symptom Management of the Patient with CKD: The Role of Dialysis
  • Peritoneal Dialysis First: Rationale
  • The Pathophysiology of the Peritoneal Membrane
  • Mice that Lack Endothelial Nitric Oxide Synthase Are Protected against Functional and Structural Modifications Induced by Acute Peritonitis
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire